Management Team

Richard Bagley

President and CEO

Richard Bagley joined Samus Therapeutics in November 2016. Most recently, Mr. Bagley served as President, Chief Operating Officer and Chief Financial Officer of ZIOPHARM Oncology. Mr. Bagley began his 45 plus year career in industry at SmithKline in product management. He was later named President of E.R. Squibb U.S. before switching to the biotechnology industry, serving in Chief Executive roles at ImmuLogic, ProSript and AltaRex and as President/COO/CFO of ZIOPHARM. In these roles, Mr. Bagley completed six major biotech-partnering transactions and raised over $500 million from corporate partnering arrangements and equity offerings. Among his product achievements, he launched Tagamet® in the US at SmithKline, positioned Capoten® for heart failure, completed the pre-launch of Pravachol® at Squibb, and led the funding of Velcade® development at ProScript. Mr. Bagley also served on a senior advisory committee at MD Anderson Cancer Center, was a member of the board of the Fox Chase Cancer Center, and a founding director of BIO (the Biotechnology Industry Organization). Mr. Bagley obtained his M.A. in Teaching in Biological Sciences from the Harvard School of Education and his B.S. in Biology from Trinity College.

Susan Duggan, RN, MBA

Principal Clinical Consultant

Susan Duggan joined Samus Therapeutics in March 2018 bringing more than 25 years of experience within healthcare, clinical research and business organizations. Prior to joining Samus, Ms. Duggan was Director, Clinical Affairs, at Medtronic, PLC a global leader in medical technology. Her broad experience spans the pharmaceutical, medical device and biotech industries in various therapeutic areas including oncology, pulmonary, cardiac, surgical and neurology. As an organizational leader, Ms. Duggan’s diverse background enabled her to implement strategic solutions, develop high performing teams and successful programs. Ms. Duggan received her bachelor’s degree from Colby Sawyer College, Associates Degree in Nursing from Northern Essex Community College and MBA from Rivier University.

Gregory Hileman, PhD

Head of Regulatory Affairs

Dr. Hileman has more than 25 years of pharmaceutical regulatory affairs experience, specializing in strategic global regulatory affairs, Food and Drug Administration (FDA) and European Medicines Agency (EMA) meeting management, project team leadership, and pharmaceutical sciences. His areas of therapeutic experience include neurology (sleep disturbances, pain, Alzheimer disease, migraine, epilepsy, seizure disorders, stroke), psychiatry (depression, anxiety, schizophrenia), drug addiction, antibiotics, oncology, reproductive health, osteoarthritis, and osteoporosis. Before joining Cato Research, Dr. Hileman served 19 years at GlaxoSmithKline, most recently as executive director of Global Discovery Regulatory Affairs. At Cato Research, Dr. Hileman is a senior director of regulatory affairs and a principal regulatory scientist in the Regulatory Strategy department, working with project teams guiding biologics, drugs, and medical devices through the regulatory process. He has authored multiple Investigational New Drug applications (INDs), Clinical Trial Applications, New Drug Applications (NDAs), Biologics License Applications, orphan drug designations, fast track designations, and breakthrough therapy applications in traditional and common technical document format, as well as final study reports, clinical protocols, annual reports (Development Safety Update Reports), United States (U.S.) pediatric study plans, European Union pediatric investigational plans, gap analyses, and other sponsor-specific reports, including submissions to European Union regulatory agencies. Dr. Hileman earned a B.S. in pharmacy from the St. Louis College of Pharmacy and a Ph.D. in pharmaceutical sciences and physical chemistry from the University of Missouri-Kansas City.

Robert Morgan, JD

Head of Development Operations

Mr. Morgan has been involved in drug development for over 30 years with experience in both large and small pharmaceutical companies covering multiple aspects of pre- and post-approval drug development. During his career Mr. Morgan has submitted and maintained multiple INDs, NDAs and international regulatory filings, including Orphan Drug Designation, Breakthrough Therapy Designation and Emergency Use Authorization, and has been the functional leader for multinational clinical studies in the United States and abroad. He has held positions of increasing responsibility in pharmaceutical research and has worked in the Development Operations setting in multiple therapeutic areas for companies such as Verastem Oncology, MediVector, Ziopharm Oncology, DuPont Pharmaceuticals, Genzyme, Serono and EPIX Pharmaceuticals. Mr. Morgan has a graduate degree in Medical Physics and is an attorney licensed in Massachusetts.

Michael Silverman, MD

Chief Medical Officer

Michael H. Silverman, MD, FACP, is a board-certified internist with over 3 decades of experience in biopharmaceutical industry clinical research, product development, and strategic planning. His pharmaceutical industry career has included positions of increasing responsibility at both global and start-up companies, where he has managed multiple pharmaceutical and biotechnology projects across a broad scope of therapeutic areas. Dr. Silverman is the principal of BioStrategics Consulting Ltd., providing strategic and technical clinical development consulting services to development-stage biotechnology and pharmaceutical companies around the world. Prior to founding his consulting company, Dr. Silverman served as Manager, KPMG Health Care Consulting; Vice President of Clinical Research at Biopure Corporation and Executive Director of Clinical Research at Telor Ophthalmic Pharmaceuticals; Director of Clinical Research at Sandoz Research Institute in East Hanover, NJ; and Clinical Project Director at Sterling-Winthrop Research Institute in Rensselaer, NY. He was in clinical practice of medicine for seven years.

Barbra Wallner, PhD

Chief Scientific Officer

Dr. Barbara Wallner joined Samus Therapeutics in January 2017. Dr. Wallner has over 30 years of experience in biotechnology companies with domestic and international operations. Her expertise ranges from establishing corporate strategies to leading company operations in research and development, business development and intellectual property management, establishing and leading corporate partnerships, coordinating multi-company project teams and academic collaborations. Dr. Wallner obtained her B.S. and Ph.D. in Biochemistry from the University of Illinois, and spent her postdoctoral fellowship in Molecular Biology at Harvard University. She started her biotechnology career as one of the first scientists at Biogen, Inc, where she invented Amevive, which obtained market approval for psoriasis. She subsequently served as Vice President of Research and Chair of Scientific Advisory Board at Immulogic, Inc. She co-founded Point Therapeutics, Inc., a biotechnology company where she served as Chief Scientific Officer, Senior Vice President of Research and Development, and Chairman of the Scientific Advisory Board. Point Therapeutics went public and was later acquired by DARA Biosciences. Dr. Wallner then took the position of Chief Scientific Officer and Senior Vice President of Research at BioTransplant, Inc. and subsequently joined ZIOPHARM Oncology as Chief Technology Officer and Senior Vice President of Technology Operations. Dr. Wallner’s areas of scientific expertise include biochemistry, molecular biology, cell biology, immunology, and small molecule and peptide chemistry. During her career Dr. Wallner authored 43 US issued patents and more than 120 patent applications published and issued world-wide.

Marc Swikalus, CPA, MBA

Vice President of Finance and Controller

Marc Swikalus joined Samus Therapeutics in April 2018 as the Director of Financial Planning & Analysis and currently serves as Vice President of Finance and Controller. Mr. Swikalus brings over 22 years of finance and accounting experience within the life science, computer software and public accounting industries. Prior to joining Samus, Mr. Swikalus served as the Manager of Accounting and Reporting at Civitas Therapeutics and Manager of Budgeting and Forecasting at Ziopharm Oncology, Inc. Mr. Swikalus obtained his BS in Accounting from Bentley University and his MBA from Western New England University.


Lead Advisors for CNS Neurodegeneration and Cancer

  • James Armitage, MD, University of Nebraska Medical Center
  • Gabriela Chiosis, PhD (Co-Founder), Memorial Sloan Kettering Cancer Center
  • Howard Coleman, MD, PhD, Huntsman Cancer Institute at the University of Utah
  • Jeffrey L. Cummings, MD, ScD, Cleveland Clinic Lou Ruvo Center for Brain Health
  • John de Groot, MD, The University of Texas MD Anderson Cancer Center
  • Howard Fillit, MD, Alzheimer’s Drug Discovery Foundation
  • David Knopman, MD, Mayo Clinic
  • Larry Norton, MD (Co-Founder), Memorial Sloan Kettering Cancer Center
  • Terry Heiman-Patterson, MD, Lewis Katz School of Medicine at Temple University
  • Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center
  • Robert Portney, MD, Massachusetts General Hospital
  • Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center